GlassScriptPhysician profile
Cesar Andres Avalos
NPI 1922459353
$6,183.53
in general payments reported to CMS, 2019-2025
36 companies · $2,501 in 2025
The $2,501 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.76 · 2020: $36.90 · 2021: $112 · 2022: $406 · 2023: $479 · 2024: $2,636 · 2025: $2,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,248 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,248.36 |
| Education | $367.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,002.14 | 2021-2025 | Tavneos, Enbrel, Krystexxa |
| Abbvie INC. | $912.15 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $896.58 | 2022-2025 | Tremfya, Simponi Aria, Tecvayli |
| Novartis Pharmaceuticals Corporation | $709.11 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $401.38 | 2021-2025 | Lupkynis |
| Ucb, INC. | $283.76 | 2020-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $237.82 | 2024-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $230.99 | 2023-2025 | Idacio |
| Glaxosmithkline, LLC. | $183.99 | 2024-2025 | Benlysta, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $172.03 | 2020-2025 | |
| Ani Pharmaceuticals, INC. | $151.60 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Scilex Pharmaceuticals INC. | $135.59 | 2024-2025 | |
| Sobi, INC | $108.97 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $88.73 | 2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $86.73 | 2025 | Acthar |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $84.28 | 2023-2024 | Taltz, Emgality |
| E.R. Squibb & Sons, L.L.C. | $77.47 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.97 | 2024 | Ofev, Cyltezo |
| Avadel Cns Pharmaceuticals, LLC | $36.32 | 2025 | Lumryz |
| Alexion Pharmaceuticals, INC. | $35.96 | 2025 | Strensiq, Ultomiris |
| United Therapeutics Corporation | $24.79 | 2023 | Tyvaso |
| Merck Sharp & Dohme LLC | $24.08 | 2019-2020 | |
| Sandoz INC. | $24.01 | 2024 | Hyrimoz |
| Depuy Synthes Sales INC. | $20.46 | 2024 | Monovisc |
| Biocon Biologics INC | $20.45 | 2025 | Yesintek |
| Corcept Therapeutics | $20.17 | 2025 | Korlym |
| Celltrion USA INC. | $19.56 | 2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $18.36 | 2025 | Fruzaqla |
| Daiichi Sankyo INC. | $18.27 | 2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $17.99 | 2024 | Monoferric |
| Abbott Laboratories | $16.61 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $16.36 | 2025 | Sunosi |
| Genzyme Corporation | $15.92 | 2023 | |
| Xeris Pharmaceuticals, INC. | $15.68 | 2024 | Gvoke Hypopen |
| Octapharma USA, INC. | $15.08 | 2025 | Octagam Immune Globulin (Human) |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Avalos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.